Cadrenal Therapeutics, Common Stock Market Value
| CVKD Stock | 14.99 0.98 7.00% |
| Symbol | Cadrenal |
Cadrenal Therapeutics, Company Valuation
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cadrenal Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cadrenal Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cadrenal Therapeutics,.
| 12/03/2022 |
| 11/22/2024 |
If you would invest 0.00 in Cadrenal Therapeutics, on December 3, 2022 and sell it all today you would earn a total of 0.00 from holding Cadrenal Therapeutics, Common or generate 0.0% return on investment in Cadrenal Therapeutics, over 720 days. Cadrenal Therapeutics, is related to or competes with Mineralys Therapeutics,, Structure Therapeutics, Centessa Pharmaceuticals, Nuvectis Pharma, Senti Biosciences, Foghorn Therapeutics, and Quoin Pharmaceuticals. Cadrenal Therapeutics, is entity of United States More
Cadrenal Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cadrenal Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cadrenal Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.87 | |||
| Information Ratio | 0.148 | |||
| Maximum Drawdown | 47.47 | |||
| Value At Risk | (7.47) | |||
| Potential Upside | 17.85 |
Cadrenal Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cadrenal Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cadrenal Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Cadrenal Therapeutics, historical prices to predict the future Cadrenal Therapeutics,'s volatility.| Risk Adjusted Performance | 0.1322 | |||
| Jensen Alpha | 1.06 | |||
| Total Risk Alpha | 0.2431 | |||
| Sortino Ratio | 0.1759 | |||
| Treynor Ratio | 0.518 |
Cadrenal Therapeutics, Backtested Returns
Cadrenal Therapeutics, is moderately volatile given 3 months investment horizon. Cadrenal Therapeutics, secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17% return per unit of standard deviation over the last 3 months. We were able to collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.37% are justified by taking the suggested risk. Use Cadrenal Therapeutics, mean deviation of 6.08, and Risk Adjusted Performance of 0.1322 to evaluate company specific risk that cannot be diversified away. Cadrenal Therapeutics, holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cadrenal Therapeutics, will likely underperform. Use Cadrenal Therapeutics, treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to analyze future returns on Cadrenal Therapeutics,.
Auto-correlation | 0.00 |
No correlation between past and present
Cadrenal Therapeutics, Common has no correlation between past and present. Overlapping area represents the amount of predictability between Cadrenal Therapeutics, time series from 3rd of December 2022 to 28th of November 2023 and 28th of November 2023 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cadrenal Therapeutics, price movement. The serial correlation of 0.0 indicates that just 0.0% of current Cadrenal Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 13.69 |
Cadrenal Therapeutics, lagged returns against current returns
Autocorrelation, which is Cadrenal Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cadrenal Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Cadrenal Therapeutics, returns to help us make a trade decision. For example, suppose you find that Cadrenal Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cadrenal Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cadrenal Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cadrenal Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cadrenal Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Cadrenal Therapeutics, Lagged Returns
When evaluating Cadrenal Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cadrenal Therapeutics, stock have on its future price. Cadrenal Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cadrenal Therapeutics, autocorrelation shows the relationship between Cadrenal Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Cadrenal Therapeutics, Common.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports:Check out Cadrenal Therapeutics, Correlation, Cadrenal Therapeutics, Volatility and Cadrenal Therapeutics, Alpha and Beta module to complement your research on Cadrenal Therapeutics,. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Cadrenal Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.